RxDoctor Payments Data

Nirav Shah, MD

Infectious Disease · Chicago, ILNPI 1992968457

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.3% of the total across 109 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Abbott accounts for 67.5% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2021 at $2,491 and has fallen 79.2% since, to $518 in 2025.

$8,251in general payments, 2019–2025

Across 109 payments — averaging $75.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$6K
  • Johnson & Johnson$754
  • Pfizer$486
  • Nalu Medical, Inc.$374
  • SPR Therapeutics, Inc$195
  • Avanos Medical$169
  • plus $700 from 8 others
$363,001in research payments, 2019–2025

Across 30 payments — averaging $12,100 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$283K
  • Pfizer$58K
  • Dompe Farmaceutici S.p.a.$22K

What the payments were for

  • Consulting fees$5807%
  • Travel & lodging$380%
  • Food & beverage$7,61992%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,251 in reported general payments places this provider in the 85th percentile of 368 infectious disease providers in Illinois.

See all infectious disease providers in Illinois

Medicare billing

Part B allowed, 2024
$39,128
Medicare patients
126
Services billed
273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →